ScripKronos Bio Inc. left most of its employees with little to be thankful for on 27 November when it announced a day before the Thanksgiving holiday in the US that in addition to CEO Norbert Bischofberger
ScripKineta, Inc. and potential partner TuHura Biosciences revealed on 19 August that enrollment is resuming in the Phase I portion of a Phase I/II study of the anti-VISTA antibody KVA12123 in advanced
ScripThe University of Texas MD Anderson Cancer Center and US/UK biotech Replay announced on 14 February that they are launching a new company, Syena, to advance research conducted at the cancer center o
ScripBiotechnology valuations generally have been on the rise in recent months, relative to general stock market indices, but there still are a number of drug developers that are having trouble gaining tra